100%
If this forum was full of shareholders invested for the TAVR we would be getting very positive commentary.
The single piece valve with EOA of 2-2.5 and tissue with 10 years clinical history of anti calcification could be a game changer if proven in humans.
Validation of its potential will have to come in the form of a deal with one or two of the leaders in this field. If this does come to fruition it will change the face of this company overnight.
SIO obviously believe they have something to offer.
Ann: Promising Interim Results from TAVR Animal Study, page-20
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.15 |
Change
0.000(0.00%) |
Mkt cap ! $291.2M | |||
| Open | High | Low | Value | Volume |
| $15.00 | $15.15 | $14.60 | $347.8K | 23.20K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 760 | $15.00 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.15 | 388 | 1 |
View Market Depth
| Last trade - 15.58pm 30/07/2024 (20 minute delay) ? |
| AVR (ASX) Chart |